MD3347360T2 - Compuși utili pentru inhibarea ROR-gama-t - Google Patents

Compuși utili pentru inhibarea ROR-gama-t

Info

Publication number
MD3347360T2
MD3347360T2 MDE20180692T MDE20180692T MD3347360T2 MD 3347360 T2 MD3347360 T2 MD 3347360T2 MD E20180692 T MDE20180692 T MD E20180692T MD E20180692 T MDE20180692 T MD E20180692T MD 3347360 T2 MD3347360 T2 MD 3347360T2
Authority
MD
Moldova
Prior art keywords
gamma
compounds useful
ror
inhibiting ror
inhibiting
Prior art date
Application number
MDE20180692T
Other languages
English (en)
Inventor
John Richard Morphy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MD3347360T2 publication Critical patent/MD3347360T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Abstract

Prezenta invenţie furnizează noi inhibitori ai ROR gama-t şi compoziţiifarmaceutice cu aceştia.
MDE20180692T 2015-09-09 2016-09-06 Compuși utili pentru inhibarea ROR-gama-t MD3347360T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
PCT/US2016/050374 WO2017044410A1 (en) 2015-09-09 2016-09-06 Compounds useful for inhibiting ror-gamma-t

Publications (1)

Publication Number Publication Date
MD3347360T2 true MD3347360T2 (ro) 2020-03-31

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180692T MD3347360T2 (ro) 2015-09-09 2016-09-06 Compuși utili pentru inhibarea ROR-gama-t

Country Status (41)

Country Link
US (1) US9598431B1 (ro)
EP (1) EP3347360B1 (ro)
JP (1) JP6282789B1 (ro)
KR (1) KR102048780B1 (ro)
CN (1) CN108026112B (ro)
AR (1) AR105821A1 (ro)
AU (1) AU2016318593B2 (ro)
BR (1) BR112018001451B1 (ro)
CA (1) CA2994732C (ro)
CL (1) CL2018000558A1 (ro)
CO (1) CO2018002440A2 (ro)
CR (1) CR20180089A (ro)
CY (1) CY1122287T1 (ro)
DK (1) DK3347360T3 (ro)
DO (1) DOP2018000066A (ro)
EA (1) EA033882B1 (ro)
EC (1) ECSP18018793A (ro)
ES (1) ES2760992T3 (ro)
HK (1) HK1249901B (ro)
HR (1) HRP20192235T1 (ro)
HU (1) HUE047950T2 (ro)
IL (1) IL257202B (ro)
JO (1) JO3638B1 (ro)
LT (1) LT3347360T (ro)
MA (1) MA42776B1 (ro)
MD (1) MD3347360T2 (ro)
MX (1) MX2018002898A (ro)
MY (1) MY195903A (ro)
NZ (1) NZ739518A (ro)
PE (1) PE20181274A1 (ro)
PH (1) PH12018500504A1 (ro)
PL (1) PL3347360T3 (ro)
PT (1) PT3347360T (ro)
RS (1) RS59655B1 (ro)
SI (1) SI3347360T1 (ro)
SV (1) SV2018005647A (ro)
TN (1) TN2018000057A1 (ro)
TW (1) TWI597284B (ro)
UA (1) UA118824C2 (ro)
WO (1) WO2017044410A1 (ro)
ZA (1) ZA201800515B (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3589637T (lt) 2017-03-02 2021-06-25 Eli Lilly And Company Junginiai, naudotini ror-gama-t slopinimui
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
WO2018193297A1 (en) 2017-04-21 2018-10-25 Cadila Healthcare Limited Novel compounds as ror-gamma modulators
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
US20240051969A1 (en) 2020-12-07 2024-02-15 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
DK2501704T3 (da) * 2009-11-16 2013-10-14 Lilly Co Eli Spiropiperidinforbindelser som oral-1-receptorantagonister
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
US8710245B2 (en) * 2009-12-04 2014-04-29 Psychogenics Inc. Multicyclic compounds and methods of use thereof
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
US9657033B2 (en) * 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
EA201791271A1 (ru) * 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators

Also Published As

Publication number Publication date
DOP2018000066A (es) 2018-03-30
CA2994732C (en) 2020-06-30
BR112018001451A2 (pt) 2018-09-11
DK3347360T3 (da) 2020-01-02
EP3347360B1 (en) 2019-10-23
CO2018002440A2 (es) 2018-07-10
MY195903A (en) 2023-02-27
BR112018001451B1 (pt) 2023-10-10
JP6282789B1 (ja) 2018-02-21
PL3347360T3 (pl) 2020-04-30
HUE047950T2 (hu) 2020-05-28
AU2016318593A1 (en) 2018-02-15
CY1122287T1 (el) 2020-11-25
HK1249901B (zh) 2020-06-19
ES2760992T3 (es) 2020-05-18
TN2018000057A1 (en) 2019-07-08
EP3347360A1 (en) 2018-07-18
CN108026112A (zh) 2018-05-11
JO3638B1 (ar) 2020-08-27
PH12018500504A1 (en) 2018-09-24
IL257202B (en) 2020-02-27
RS59655B1 (sr) 2020-01-31
SI3347360T1 (sl) 2019-12-31
IL257202A (en) 2018-03-29
AU2016318593B2 (en) 2018-10-04
TWI597284B (zh) 2017-09-01
PT3347360T (pt) 2020-01-07
TW201722964A (zh) 2017-07-01
EA033882B1 (ru) 2019-12-05
MX2018002898A (es) 2018-06-18
UA118824C2 (uk) 2019-03-11
KR102048780B1 (ko) 2019-11-27
NZ739518A (en) 2019-06-28
PE20181274A1 (es) 2018-08-03
CR20180089A (es) 2018-02-27
US9598431B1 (en) 2017-03-21
EA201890364A1 (ru) 2018-08-31
SV2018005647A (es) 2018-07-23
CL2018000558A1 (es) 2018-08-10
JP2018507203A (ja) 2018-03-15
US20170066781A1 (en) 2017-03-09
CN108026112B (zh) 2020-04-10
MA42776B1 (fr) 2020-02-28
ZA201800515B (en) 2019-06-26
KR20180031777A (ko) 2018-03-28
ECSP18018793A (es) 2018-04-30
CA2994732A1 (en) 2017-03-16
WO2017044410A1 (en) 2017-03-16
HRP20192235T1 (hr) 2020-03-20
AR105821A1 (es) 2017-11-15
LT3347360T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2018011194A (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12016500895B1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
PH12017502028A1 (en) Vortioxetine pyroglutamate
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
CY1124258T1 (el) ΕΝΩΣΕΙΣ ΧΡΗΣΙΜΕΣ ΓΙΑ ΑΝΑΣΤΟΛΗ ROR-γ-t
EA201790392A1 (ru) Фармацевтическая упаковка
NO20161136A1 (en) Compounds and compositions for biofilm prevention
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors